Novartis AG (NYSE:NVS) gapped down before the market opened on Tuesday . The stock had previously closed at $79.17, but opened at $79.94. Novartis AG shares last traded at $81.13, with a volume of 836,897 shares.

NVS has been the topic of a number of recent analyst reports. Citigroup Inc. restated a “neutral” rating on shares of Novartis AG in a research note on Tuesday, May 24th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis AG in a report on Thursday, May 26th. Zacks Investment Research raised shares of Novartis AG from a “sell” rating to a “hold” rating in a report on Wednesday, June 15th. TheStreet raised shares of Novartis AG from a “hold” rating to a “buy” rating in a report on Friday, June 24th. Finally, Bank of America Corp. reaffirmed a “hold” rating on shares of Novartis AG in a report on Tuesday, July 12th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $91.83.

The company has a market capitalization of $193.02 billion, a P/E ratio of 28.94 and a beta of 0.58. The stock has a 50 day moving average price of $80.80 and a 200 day moving average price of $78.33.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/novartis-ag-nvs-shares-gap-down-to-79-94.html

Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.05. The firm earned $12.47 billion during the quarter, compared to analysts’ expectations of $12.33 billion. Novartis AG had a return on equity of 15.33% and a net margin of 13.84%. During the same period in the previous year, the firm posted $1.25 earnings per share. Analysts anticipate that Novartis AG will post $4.73 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. Macquarie Group Ltd. boosted its position in Novartis AG by 3.8% in the second quarter. Macquarie Group Ltd. now owns 1,495,947 shares of the company’s stock worth $123,431,000 after buying an additional 54,614 shares during the period. Williams Jones & Associates LLC boosted its position in Novartis AG by 28.3% in the second quarter. Williams Jones & Associates LLC now owns 7,610 shares of the company’s stock worth $628,000 after buying an additional 1,680 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in Novartis AG by 7.1% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 36,451 shares of the company’s stock worth $3,008,000 after buying an additional 2,424 shares during the period. CAPROCK Group Inc. boosted its position in Novartis AG by 6.8% in the second quarter. CAPROCK Group Inc. now owns 21,060 shares of the company’s stock worth $1,738,000 after buying an additional 1,337 shares during the period. Finally, Royal Bank of Canada boosted its position in Novartis AG by 8.0% in the second quarter. Royal Bank of Canada now owns 1,155,783 shares of the company’s stock worth $95,365,000 after buying an additional 85,210 shares during the period. 9.78% of the stock is owned by institutional investors.

Novartis AG Company Profile

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

5 Day Chart for NYSE:NVS

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.